Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Syndax: When Does the Revenue Ramp Start Covering the Cash Burn Story? Barchart - Wed Apr 29, 4:22PM CDT

Barchart Research What to Expect from SNDX Earnings SNDX Generated April 29, 2026 Current Price $20.63 EPS Estimate $$-0.58 Consensus Rating Strong Buy Average Move 10.13% Syndax: When Does the Revenue...

SNDX : 20.63 (-2.27%)
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 GlobeNewswire - Fri Apr 24, 6:00AM CDT

NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report...

SNDX : 20.63 (-2.27%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Fri Apr 3, 3:01PM CDT

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1,...

SNDX : 20.63 (-2.27%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Wed Mar 4, 3:01PM CST

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1,...

SNDX : 20.63 (-2.27%)
Syndax: Q4 Earnings Snapshot AP - Thu Feb 26, 4:02PM CST

Syndax: Q4 Earnings Snapshot

SNDX : 20.63 (-2.27%)
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Thu Feb 26, 3:01PM CST

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025...

SNDX : 20.63 (-2.27%)
Syndax Announces Participation in March Investor Conferences GlobeNewswire - Mon Feb 23, 6:00AM CST

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 20.63 (-2.27%)
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 GlobeNewswire - Thu Feb 19, 6:00AM CST

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report...

SNDX : 20.63 (-2.27%)
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit GlobeNewswire - Thu Feb 5, 6:00AM CST

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 20.63 (-2.27%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Wed Feb 4, 3:01PM CST

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on February...

SNDX : 20.63 (-2.27%)

Barchart Exclusives

Following UAE’s OPEC Exit Shock, Diamondback Energy Could Be the Smartest Bet Now Barchart - 48 minutes ago
The UAE’s decision to exit OPEC/OPEC+ has injected new uncertainty into oil markets and pushed crude prices above $100 per barrel. Low-cost Permian operator Diamondback Energy may be positioned as one of the clearest near-term beneficiaries. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.